Prior Authorization Legislation Takes Center Stage at Joint Hearing on Health Care Affordability
A joint hearing held on Jan. 22 by the U.S. House of Representatives Energy & Commerce Subcommittee on Health and the Ways and Means Committee hosted...
The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.
The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.
Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.
Sources:
https://www.reginfo.gov/public/do/eoDetails?rrid=1044563
https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf
https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3
Payer Update for Blue Cross Blue Shield New Jersey
TELCOR has identified ongoing processing challenges with BCBS New Jersey that laboratories should be aware of. When claims require medical records,...
Payer Update for BCBS Nebraska
TELCOR has identified a recent process change with BCBSNebraska impacting payment timelines. As of November 1, 2025, BCBSNE adjustedits payment...